Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00453583 · ClinicalTrials.gov registry record

Evaluation of Treatment Satisfaction in Children With an Allergy and Who Received an Antihistamine

A clinical trial, sponsored by UCB Pharma.

Completed
Registry status
4,581
Enrollment target

NCT00453583: Completed study, sponsored by UCB Pharma.

NCT00453583 is a clinical trial that has completed, run by UCB Pharma. The registered enrollment target is 4,581 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00453583 has completed, sponsored by UCB Pharma.

COMPLETED
Registry status
4,581 participants
Enrollment target

Study Summary

This is a non-interventional retrospective data collection study from children aged from 2 to 12 years old diagnosed with an allergy and who received a treatment consisting of an H1-antihistamine. The period of last taken medication will be observed to evaluate the global satisfaction of the parents and physician for this last treatment.

Trial Details

FieldValue
Enrollment Target 4,581 participants
Start Date 2007-03
Est. Completion 2008-01
UCB Pharma

100 total trials

What the finished NCT00453583 record still lists

NCT00453583 is an observational study that tracks outcomes without assigning an intervention. Its 4,581 participants enrollment target places it among the larger protocols in the corpus.

The record links to 0 conditions, and to 0 interventions.

NCT00453583 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00453583 about?

NCT00453583 is a clinical study titled "Evaluation of Treatment Satisfaction in Children With an Allergy and Who Received an Antihistamine". This is a non-interventional retrospective data collection study from children aged from 2 to 12 years old diagnosed with an allergy and who received a treatment consisting of an H1-antihistamine. The period of last taken medication will be observed to evaluate the global satisfaction of the parents...

What is the current status of trial NCT00453583?

This trial is currently completed. The enrollment target is 4,581 participants. The study started on 2007-03. Estimated completion is 2008-01.

Who is sponsoring clinical trial NCT00453583?

This trial is sponsored by UCB Pharma, which has 100 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05768217 · 4,600 participants · NA

    Community Resiliency Collective Efficacy Intervention

  • NCT06535139 · 4,630 participants · NA

    ReMARK: Addressing Disparities in Rural HPV-related Cancer Prevention

  • NCT06702878 · 4,514 participants · Phase 3

    Light-Activated Antimicrobial Therapy to Prevent Surgical Site Infections

  • NCT06533111 · 4,500 participants · NA

    Improving Surgical Patient Outcomes Through Implementation of a SemiStructured Intraoperative Anesthesia Handoff Tool

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00453583, the US trial registry maintained by the National Library of Medicine. NCT00453583 (large enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.